BA-2017(BA-2017) - 药物靶点：ROCK2_在研适应症：脊髓损伤_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

ROCK2

作用机制

ROCK2抑制剂(Rho相关蛋白激酶-2抑制剂)

治疗领域

神经系统疾病其他疾病

在研适应症

脊髓损伤

非在研适应症-

原研机构

BioAxone Therapeutic, Inc.

在研机构

BioAxone Therapeutic, Inc.

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 BA-2017 相关的临床结果

登录后查看更多信息

100 项与 BA-2017 相关的转化医学

登录后查看更多信息

100 项与 BA-2017 相关的专利（医药）

登录后查看更多信息

1

项与 BA-2017 相关的文献（医药）

1997-02-01·General Pharmacology: The Vascular System

β-adrenergic receptor and platelet inhibitory activities of a new series of trimetoquinol and related benzazepine analogs

Article

作者: Michael T. Clark ; Karl J. Romstedt ; Dennis R. Feller ; Gamal Shams ; Duane D. Miller ; Laura A. Lust

1. A series of dimethoxy and methylenedioxy analogs of trimetoquinol (TMQ) and structurally related 7-membered ring benzazepines (BA) were evaluated for their pharmacological effects in beta-adrenergic (atria, trachea) and thromboxane A2/prostaglandin H2 receptor systems (aorta, platelets). 2. Results show that both the 6,7-dihydroxy (catechol) moiety of trimetoquinol and an intact tetrahydroisoquinoline nucleus are essential for maintaining potent beta-stimulating and antithromboxane A2 activities. 3. By contrast, ring enlargement, as in the BA analogs, or masking of the catechol with dimethoxy or methylenedioxy functional groups enhanced the potency of inhibitors on thromboxane A2-independent activation of human platelets induced by bacterial phospholipase C (PLC). 4. The selective blockade of this pathway by these compounds suggests that they may represent a new and novel class of antiplatelet drugs.

100 项与 BA-2017 相关的药物交易

登录后查看更多信息